



(51) International Patent Classification:

C07K 16/10 (2006.01) A61K 47/48 (2006.01)
C07K 16/28 (2006.01)

(21) International Application Number:

PCT/EP2014/055311

(22) International Filing Date:

17 March 2014 (17.03.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/792,730 15 March 2013 (15.03.2013) US

(71) Applicants: **AMGEN RESEARCH (MUNICH) GMBH** [DE/DE]; Staffelseestr. 2, 81477 Munich (DE). **VIB VZW** [BE/BE]; Rijvisschestraat 120, B-9052 Gent (BE). **UNIVERSITEIT GENT** [BE/BE]; Sint-Pietersnieuwstraat 25, B-9000 Gent (BE).

(72) Inventors: **KUFER, Peter**; c/o Amgen Research (Munich) GmbH, Staffelseestr. 2, 81477 Munich (DE). **RAUM, Tobias**; c/o Amgen Research Munich GmbH, Staffelseestr. 2, 81477 Munich (DE). **MUENZ, Markus**; c/o Amgen Research Munich GmbH, Staffelseestr. 2, 81477 Munich (DE). **PENDZIALEK, Jochen**; c/o Amgen Research Munich GmbH, Staffelseestr. 2, 81477 Munich (DE). **FIERS, Walter**; Beukendreef 3, B-9070 Destelbergen (BE). **SAELENS, Xavier**; Sportstraat 18, B-8900 Ieper (BE). **ROOSE, Kenny**; Dorpsstraat 136, B-8460 Ettelgem (BE).

(74) Agents: **KOCH, Andreas** et al.; Schiweck Weinzierl Koch, Landsberger Str. 98, 80339 Munich (DE).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: ANTIBODY CONSTRUCTS FOR INFLUENZA M2 AND CD3

(57) Abstract: The present invention relates to an antibody construct comprising a first human binding domain specific for the extra-cellular part of the influenza envelope protein M2 (M2e) and a second domain specific for CD3. Moreover, the invention provides a nucleic acid molecule encoding the antibody construct, a vector comprising said nucleic acid molecule and a host cell transformed or transfected with said nucleic acid molecule or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a pharmaceutical composition comprising said antibody construct, a medical use / method of treatment relating to said antibody construct, and a kit comprising said antibody construct.

